20:06 , Apr 24, 2019 |  BC Extra  |  Financial News

Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc. (South...
19:01 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Impel raises $67.5M series D

Impel NeuroPharma Inc. (Seattle, Wash.) hopes to accelerate its clinical portfolio of intranasal CNS therapies with a $67.5 million series D round led by new investors KKR and Norwest Venture Partners. Existing investors 5AM Ventures,...
11:45 , Dec 6, 2018 |  BC Extra  |  Financial News

Impel raises $67.5M series D

Impel NeuroPharma Inc. (Seattle, Wash.) hopes to accelerate its clinical portfolio of intranasal CNS therapies with a $67.5 million series D round led by new investors KKR and Norwest Venture Partners. Existing investors 5AM Ventures,...
22:34 , Jan 6, 2017 |  BC Week In Review  |  Company News

Shin Nippon Biomedical spins out Satsuma

Shin Nippon spun out Satsuma Pharmaceuticals Inc. (San Francisco, Calif.). The newco said that it plans to begin a clinical trial of migraine candidate STS101 "in about a year." STS101 is a dry-powder nasal formulation...
00:55 , Jan 6, 2017 |  BC Extra  |  Financial News

Shin Nippon spins out Satsuma with $12M series A

Shin Nippon Biomedical Laboratories Ltd. (Tokyo:2395) spun out migraine company Satsuma Pharmaceuticals Inc. (San Francisco, Calif.) with a $12 million series A round co-led by RA Capital Management and TPG Biotech. Satsuma plans to develop...
00:32 , Dec 2, 2016 |  BC Extra  |  Financial News

Impel raising $36M series C round

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) raised $21 million in the first tranche of a planned $36 million series C round from new investors venBio, 5AM Ventures and Vivo Capital. The company is...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Paratek Pharmaceuticals Inc, Transcept deal

Infectious disease company Paratek will reverse-merge with Transcept in a stock deal. Transcept will issue Paratek stockholders about 167.5 million Transcept shares, valued at $333.3 million based on Transcept’s close of $1.99 on June 30,...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Semprana dihydroergotamine regulatory update

Allergan said FDA issued the third complete response letter for a resubmitted NDA for Semprana dihydroergotamine for the acute treatment of migraines in adults. The company said the 2 specific items listed in the letter...
08:00 , Jan 6, 2014 |  BioCentury  |  Finance

4Q Stock Wrap-Up: All's well that ends well

Although two segments lost ground in 4Q13, all of biotech's market cap groups finished 2013 in the black. Large caps valued at more than $5 billion led the way in the fourth quarter, tacking on...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Company News

Retrophin, Transcept, Roumell Asset Management LLC deal

Retrophin withdrew its unsolicited offer to acquire all shares of Transcept that Retrophin does not already own for $4 per share in cash. In September, Transcept's board unanimously rejected the offer, which valued Transcept at...